Smith & Nephew plc (LON:SN)
London · Delayed Price · Currency is GBP · Price in GBX 1,220.00
-31.50 (-2.52%)
Mar 19, 2026, 8:34 AM GMT
Revenue by Geography
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | Dec '18 Dec 31, 2018 | Dec '17 Dec 31, 2017 | Dec '16 Dec 31, 2016 | Dec '15 Dec 31, 2015 | Dec '14 Dec 31, 2014 | Dec '13 Dec 31, 2013 | Dec '12 Dec 31, 2012 |
US Revenue | 3.31B | 3.12B | ||||||||||||
US Revenue Growth | 5.86% | 4.83% | ||||||||||||
Other Established Markets Revenue | 1.86B | 1.71B | ||||||||||||
Other Established Markets Revenue Growth | 8.67% | 5.96% | ||||||||||||
Total Established Markets Revenue | 5.16B | 4.83B | ||||||||||||
Total Established Markets Revenue Growth | 6.85% | 5.23% | ||||||||||||
Emerging Markets Revenue | 1.00B | 980.00M | ||||||||||||
Emerging Markets Revenue Growth | 2.35% | 2.19% | ||||||||||||
Revenue (Total) | - | 5.81B | ||||||||||||
Revenue (Total) Growth | - | 4.70% |
Revenue
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | Dec '18 Dec 31, 2018 | Dec '17 Dec 31, 2017 | Dec '16 Dec 31, 2016 | Dec '15 Dec 31, 2015 | Dec '14 Dec 31, 2014 | Dec '13 Dec 31, 2013 | Dec '12 Dec 31, 2012 |
Knee Implants Revenue | 1.01B | 977.00M | ||||||||||||
Knee Implants Revenue Growth | 3.48% | 3.94% | ||||||||||||
Hip Implants Revenue | 641.00M | 619.00M | ||||||||||||
Hip Implants Revenue Growth | 3.55% | 3.34% | ||||||||||||
Other Reconstruction Revenue | 136.00M | 101.00M | ||||||||||||
Other Reconstruction Revenue Growth | 34.65% | -9.01% | ||||||||||||
Trauma & Extremities Revenue | 649.00M | 608.00M | ||||||||||||
Trauma & Extremities Revenue Growth | 6.74% | 7.80% | ||||||||||||
Total Orthopaedics Revenue | 2.44B | 2.31B | ||||||||||||
Total Orthopaedics Revenue Growth | 5.73% | 4.11% | ||||||||||||
Sports Medicine Joint Repair Revenue | 1.07B | 982.00M | ||||||||||||
Sports Medicine Joint Repair Revenue Growth | 8.66% | 3.91% | ||||||||||||
Arthroscopic Enabling Technologies Revenue | 647.00M | 632.00M | ||||||||||||
Arthroscopic Enabling Technologies Revenue Growth | 2.37% | 7.48% | ||||||||||||
ENT (Ear, Nose and Throat) Revenue | 220.00M | 210.00M | ||||||||||||
ENT (Ear, Nose and Throat) Revenue Growth | 4.76% | 7.14% | ||||||||||||
Total Sports Medicine & ENT Revenue | 1.93B | 1.82B | ||||||||||||
Total Sports Medicine & ENT Revenue Growth | 6.03% | 5.50% | ||||||||||||
Advanced Wound Care Revenue | 766.00M | 735.00M | ||||||||||||
Advanced Wound Care Revenue Growth | 4.22% | 1.38% | ||||||||||||
Advanced Wound Bioactives Revenue | 621.00M | 581.00M | ||||||||||||
Advanced Wound Bioactives Revenue Growth | 6.88% | 5.06% | ||||||||||||
Advanced Wound Devices Revenue | 406.00M | 365.00M | ||||||||||||
Advanced Wound Devices Revenue Growth | 11.23% | 11.28% | ||||||||||||
Total Advanced Wound Management Revenue | 1.79B | 1.68B | ||||||||||||
Total Advanced Wound Management Revenue Growth | 6.66% | 4.67% | ||||||||||||
Revenue (Total) | - | 5.81B | ||||||||||||
Revenue (Total) Growth | - | 4.70% |
Adjusted EBIT
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | Dec '18 Dec 31, 2018 | Dec '17 Dec 31, 2017 | Dec '16 Dec 31, 2016 | Dec '15 Dec 31, 2015 | Dec '14 Dec 31, 2014 | Dec '13 Dec 31, 2013 | Dec '12 Dec 31, 2012 |
Orthopaedics Segment Profit | 363.00M | 265.00M | ||||||||||||
Orthopaedics Segment Profit Growth | 36.98% | 5.58% | ||||||||||||
Sports Medicine & ENT Segment Profit | 461.00M | 437.00M | ||||||||||||
Sports Medicine & ENT Segment Profit Growth | 5.49% | 10.91% | ||||||||||||
Advanced Wound Management Segment Profit | 447.00M | 399.00M | ||||||||||||
Advanced Wound Management Segment Profit Growth | 12.03% | 7.26% | ||||||||||||
Operating Income (Other) | - | -444.00M | ||||||||||||
Operating Income (Total) | - | 657.00M | ||||||||||||
Operating Income (Total) Growth | - | 54.59% |
Updated Dec 31, 2025. Data Source: Fiscal.ai.